patent.fyi
Applications  /  US 2026/0354358
United States Patent Application Publication

US 2026/0354358 A1

Published
Nov 12, 2026
Filed
Oct 6, 2023
Earliest date on the face
Oct 7, 2022
Classification
A01K 67/0275
First published here
Nov 18, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Transient FAH messenger RNA

What ifWhat if host hepatocytes receive FAH messenger RNA from lipid nanoparticles?
Claim language“modified with an inducible promoter”

Lipid nanoparticles deliver capped, polyadenylated FAH messenger RNA to host hepatocytes. Ribosomes translate the delivered RNA, and the amount of supplemental FAH falls as the RNA and protein turn over.

1.1Liver-directed splice switching

What ifWhat if an antisense oligonucleotide restores productive splicing of FAH transcripts?
Claim language“modified with an inducible promoter”

A constitutive promoter drives an FAH cassette containing a synthetic intron with a stop-containing exon. A splice-switching oligonucleotide masks a splice site of that exon, promotes exon skipping, and restores the FAH reading frame in mature messenger RNA.

1.2Upstream metabolic inhibition

What ifWhat if a metabolic inhibitor controls the buildup of toxic tyrosine breakdown products while host FAH activity stays deficient?
Claim language“control of the expression of FAH”

A small-molecule inhibitor blocks 4-hydroxyphenylpyruvate dioxygenase upstream of FAH and reduces the formation of fumarylacetoacetate. Withdrawing the inhibitor restores pathway flux and favors transplanted hepatocytes with functional FAH.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Food chemistry assays with hepatocytes

The inducible FAH arrangement supplies expanded primary human hepatocytes for food chemistry studies. The recovered hepatocytes are plated in multiwell culture plates and exposed to purified dietary compounds alongside vehicle controls. Liquid chromatography tracks the disappearance of each parent compound and the appearance of its metabolites.

Component substitution

Electronic simulation of inducible FAH

A microcontroller and a two-position switch replace the inducible promoter and chemical inducer in a bench simulator. The switch supplies the inducer state, and the microcontroller updates a numerical FAH state using separate rise and fall time constants. A digital-to-analog converter sends the simulated FAH signal to the monitoring hardware for testing.

Parameter or scale variation

Two plate formats for enzyme assays

A downstream enzyme assay uses either a 96-well plate with 100 microliters per well or a 384-well plate with 25 microliters per well. Each format receives the same concentration of recovered hepatocytes and the same substrate concentration. The calculation divides the measured product formation rate by the viable cell count in each well.

Combination with existing systems

Expanded hepatocytes in perfused culture

A single-pass perfusion system receives hepatocytes recovered from the bioincubator. A pump moves medium from a reservoir through a bubble trap and a cell chamber with a collagen-coated growth surface. An outlet sampler collects effluent for albumin and urea measurements, and the measured flow rate converts concentrations to secretion rates.

Automated or data-driven variant

Automated tracking of FAH measurements

A laboratory database links inducer administration records and FAH assay results to the same animal identifier. Software aligns records by timestamp and plots measured FAH values against the recorded inducer state. The dashboard flags missing samples and displays albumin and bilirubin measurements on separate tracks for review.

Image analysis of donor cell fraction

A slide scanner captures liver sections stained for a donor-specific nuclear marker and a general nuclear counterstain. Image analysis segments nuclei in the counterstain channel and classifies each nucleus using the signal from the donor marker channel. Software reports the fraction of nuclei positive for the donor marker by section and links the results to the corresponding FAH measurements.

Specific version of a part

Drug-controlled FAH protein turnover

A constitutive promoter produces FAH fused to a tag that recruits a cellular ubiquitin ligase in the presence of a small molecule. Dosing directs the tagged FAH to the proteasome, and withdrawal lets newly synthesized FAH accumulate.

Single switch by recombination

A constitutive liver promoter sits upstream of an FAH coding sequence separated by a transcriptional stop cassette. Recombinase translated from delivered messenger RNA excises the stop cassette at paired recognition sites, and FAH transcription continues after the recombinase clears.

Inducible FAH transgene cassette

An integrated cassette places an FAH coding sequence downstream of tetracycline operator repeats and a minimal promoter. A separate hepatocyte-active promoter supplies a reverse tetracycline-responsive transactivator that binds the operators in the presence of a tetracycline-class inducer.

Endogenous FAH promoter replacement

A tetracycline-responsive promoter replaces the native promoter at the endogenous FAH locus. The replacement promoter drives transcription through the existing FAH exons and introns when the inducer-bound transactivator occupies its operator sites.

Inducer activates FAH transcription

A reverse tetracycline-responsive transactivator binds a tetracycline-class inducer and occupies operator sites upstream of the FAH promoter. Promoter activity falls after inducer withdrawal, and FAH abundance declines as the existing messenger RNA and protein turn over.

Inducer suppresses FAH transcription

A tetracycline-responsive transactivator binds upstream operator sites and activates the FAH promoter in the absence of an inducer. Adding a tetracycline-class inducer prevents operator binding and lowers FAH transcription.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2013/0007913 A1
Published
Jan 3, 2013
Filed
Apr 2, 2012
Class
C12N 5/10
Document BUS 2014/0373187 A1
Published
Dec 18, 2014
Filed
Aug 24, 2012
Class
A01K 67/0278
Claim 1
Document A
Document B
1.1an FAH transgene or endogenous FAH modified with an inducible promoter,
Generally, the expression vector will include a promoter. The promoter can be inducible or constitutive.
B · US 2014/0373187 A1 · ¶ 171
1.2wherein the inducible promoter allows for control of the expression of FAH in the presence or absence of an inducer.
If inducible, there are sequences present therein which mediate regulation of expression so that the associated sequence is transcribed only when an inducer molecule is present.
A · US 2013/0007913 A1 · ¶ 112
The promoter can be inducible or constitutive.
B · US 2014/0373187 A1 · ¶ 171

An empty cell means only that no passage was reproduced there.

Statements in these documents
There have been increasing threats from terrorists which present an urgent need for simple and robust detectors for harmful biological or chemical agents.
A · US 2013/0007913 A1 · ¶ 5
The high and continuous cost significantly limits the ability to detect biological and chemical weapons as well as environmental pollutants.
A · US 2013/0007913 A1 · ¶ 5
This disclosure also relates to methods of using such animal models, including expanding heterologous hepatocytes, such as human hepatocytes, in such animal models.
B · US 2014/0373187 A1 · ¶ 5
The availability of high quality human hepatocytes is further hampered by the fact that they cannot be significantly expanded in tissue culture.
B · US 2014/0373187 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0354358 A1, claim 1, first published 2026-11-18T21:55:14-05:00, https://patent.fyi/US20260354358/, SHA-256 a45caa6005f7cd7029fbecd357059685dd6f536cb2b6ad37c026f3faaf92af5b
First published
Permanent addresshttps://patent.fyi/US20260354358/
Content fingerprint (SHA-256)a45caa6005f7cd7029fbecd357059685dd6f536cb2b6ad37c026f3faaf92af5b
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi